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Objectives The goal of this study was to evaluate the influence of left ventricular (LV) lead position on the risk of ventricular
tachyarrhythmia in patients undergoing cardiac resynchronization therapy (CRT).
Background Left ventricular ejection fraction (LVEF) is a surrogate marker of heart failure (HF) status and associated risk.
Data on the effectiveness of cardiac resynchronization therapy with defibrillator (CRT-D) in patients with mild HF
and better LVEF are limited.
Methods In the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Ther-
apy) study, the echocardiography core laboratory assessed baseline LVEF independent of the enrolling centers
and identified a range of LVEFs, including those 30% (i.e., beyond the eligibility criteria). Echocardiographic
response with CRT, defined as percent change in left ventricular end-diastolic volume (LVEDV), was analyzed in 3
prespecified LVEF groups: 30%, 26% to 30%, and 25%. The primary endpoint was HF or death. Secondary
endpoint included all-cause mortality.
Results LVEF was evaluated in 1,809 study patients. There were 696 (38%) patients with LVEF 30% (in the range of 30.1%
to 45.3%); 914 patients (50.5%) with LVEF 26% to 30%; and 199 patients with LVEF 25% (11%). The mean reduc-
tion in LVEDV with CRT-D therapy at the 1-year follow-up was directly related to increasing LVEF (LVEF 30%: 22.3%;
LVEF 26% to 30%: 20.1%; and LVEF 25%: 18.7% reduction, respectively [p  0.001]). CRT-D treatment similarly
reduced the risk of HF/death in patients with LVEF 30% (hazard ratio [HR]:  0.56 [95% confidence interval (CI):
0.39 to 0.82], p  0.003), LVEF 26% to 30% (HR: 0.67: [95% CI: 0.50 to 0.90], p  0.007), and LVEF 25% (HR:
0.57 [95% CI: 0.35 to 0.95], p  0.03; all p values for LVEF-by-treatment interactions 0.1).
Conclusions In MADIT-CRT, the clinical benefit of CRT was evident regardless of baseline LVEF, including those with LVEF 30%,
whereas the echocardiographic response was increased with increasing LVEF, indicating that CRT might benefit pa-
tients with better LVEF. (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy [MADIT-
CRT]; NCT00180271) (J Am Coll Cardiol 2013;61:936–44) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.051Cardiac resynchronization therapy (CRT) has been shown
to reduce heart failure (HF) symptoms, hospitalizations,
and mortality in patients with moderate or severe drug-
refractory HF, severely depressed left ventricular ejection
fraction (LVEF), and prolonged QRS interval (1–3). CRT
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March 5, 2013:936–44 LVEF and CRTstudy, the RAFT (Resynchronization/Defibrillation in Ambu-
latory Heart Failure Trial) study, and the REVERSE (Resyn-
chronization Reverses Remodeling in Systolic Left Ventricular
Dysfunction) trial have further broadened CRT indication to
patients with mild HF (5–7).
See page 945
Using the preselected cutoff point of left ventricular
ejection fraction (LVEF) as inclusion criterion for CRT is
considered an arbitrary method. Patients develop HF across
the spectrum of LVEF. Depressed LVEF was shown to be
a surrogate marker of HF status and is associated with
increased risk of adverse events, all-cause mortality, and
sudden cardiac death (8–10). However, the risk associated
with LVEF is a continuum until the cutoff point of 45% (9).
Therefore, there is a rationale for CRT in patients with less
depressed LVEF.
In MADIT-CRT, inclusion criteria comprised patients
with LVEF 30% as evaluated by enrolling centers before
enrollment. All patients additionally underwent central
echocardiographic analysis of LVEF in the study core
laboratory of Brigham and Women’s Hospital, Harvard
Medical School, Boston, Massachusetts, where a substantial
proportion of patients were identified as having LVEF
30%, which is beyond the eligibility criteria. This provides
a unique opportunity to evaluate the efficacy of cardiac
resynchronization therapy with defibrillator (CRT-D) in
patients with less decreased cardiac function.
The aims of the current study were to evaluate the
relationship between LVEF and the following: 1) the
clinical outcomes of patient with mild HF enrolled in
MADIT-CRT; 2) the echocardiographic response to
CRT-D in the trial; and 3) the clinical benefit of CRT-D,
with a specific focus on the subset of patients with more
preserved LVEF enrolled in the trial.
Methods
Study population. The design, protocol, and results of
MADIT-CRT have been published previously (11,12).
Briefly, 1,820 patients with ischemic cardiomyopathy (New
York Heart Association [NYHA] functional class I or II) or
nonischemic cardiomyopathy (NHYA functional class II
only), LVEF 30%, and a prolonged QRS duration 130
ms were randomized to receive CRT-D or implantable
cardioverter-defibrillator (ICD) therapy in a 3:2 ratio. All
eligible patients met the guideline criteria for ICD (13).
Patients were excluded if they were aged 21 years, if they
had existing indication for CRT, implanted pacemaker,
NYHA III or IV functional class in the past 90 days before
enrollment, coronary artery bypass graft surgery, or percu-
taneous coronary intervention or myocardial infarction
within the past 90 days before enrollment. A total of 110
hospital centers from North America and Europe partici-
pated in this international multicenter trial. The study wasin compliance with the Declara-
tion of Helsinki, and all enrolling
sites had the protocol approved by
the local institutional review
board. All patients provided writ-
ten informed consent before
enrollment.
Patients were excluded from
the current study if their baseline
LVEF measurement was not
available due to missing images
or poor quality of echocardio-
graphic images. Accordingly, the
study sample comprised 1,809
(99%) of the 1,820 patients en-
rolled in MADIT-CRT; 1,074
(60%) were randomized to
CRT-D therapy. The baseline
analysis was performed on an
intention-to-treat basis.
Data acquisition and patient
follow-up. The MADIT-CRT
trial was conducted from De-
cember 22, 2004, through June 22, 2009. After device
implantation, patients had an ambulatory follow-up at 1
month and every 3 months thereafter until the termination
of the trial. The mean follow-up of the enrolled patients was
29.4 months. All patients had clinical evaluation at each
follow-up visit or at any meaningful clinical event.
Echocardiographic methods. Echocardiograms were ob-
tained according to a study-specific protocol at baseline, which
was before device implantation (n  1,809), and at 1 year.
Paired echocardiograms from baseline and at 12 months with
device turned on were available in 1,372 patients (623 patients
in the ICD-only group and 749 in the CRT-D group).
Echocardiography investigators and sonographers were
qualified to perform echocardiography according to the
approved echocardiography protocol. Recordings were ana-
lyzed off-line at the Brigham and Women’s Hospital as an
independent echocardiography core laboratory. Echocardi-
ography investigators analyzing the images were blinded to
treatment assignment or clinical outcome.
Left ventricular volumes were measured by using Simp-
son’s disk method in the apical 4- and 2-chamber views, and
LVEF was calculated according to the established American
Society of Echocardiography protocols (14). The coeffi-
cients of variation for end-diastolic volume, end-systolic
volume, and LVEF were 5.2%, 6.2%, and 5.5%, respec-
tively, as reported previously (4).
Left ventricular mechanical dyssynchrony was measured
by using B-mode speckle tracking software (TomTec Im-
aging Systems, Unterschleissheim, Germany), as reported
previously (15). Left ventricular mechanical dyssynchrony
was determined as the SD of regional time-to-peak trans-
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CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization therapy
with defibrillator
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cardioverter-defibrillator
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LVEF and CRT March 5, 2013:936–44segments (septum, lateral, anterior, and inferior walls basal,
mid- and apical segments) of the left ventricle.
Definitions and endpoints. Patients with baseline LVEF
measurements were divided into 3 prespecified groups based
on the echocardiography core laboratory assessment: LVEF
25%, LVEF 26% to 30% (classic criterion), and LVEF
30% (beyond the eligibility criteria).
The primary endpoint of the current study was the first
occurrence of an HF episode or death from any cause.
Secondary endpoint included all-cause mortality.
The diagnosis of HF was made by physicians unblinded
to treatment assignment, if patients were exhibiting signs
and symptoms consistent with congestive HF that resulted
in intravenous decongestive treatment in an outpatient
setting or augmented decongestive therapy with oral or
parenteral medications during an in-hospital stay. Adjudi-
cation of the endpoints (both HF/death and death) was
conducted by an independent mortality committee and by
an HF committee unaware of treatment assignments, ac-
cording to prespecified criteria, as described previously (11).
When analyzing the echocardiographic response to CRT,
we evaluated the left ventricular end-diastolic volume
(LVEDV), left ventricular end-systolic volume (LVESV),
and left atrial volume (LAV) percent changes at the 12-
month follow-up in all 3 LVEF groups.
The left ventricular remodeling effect of CRT-D was
defined as percent reduction in LVEDV between enroll-
ment and 1-year echocardiogram (calculated as the differ-
ence between 1-year and baseline LVEDV, divided by
baseline LVEDV). The left atrial remodeling effect of
CRT-D was defined as percent reduction in LAV between
enrollment and 1-year echocardiogram (calculated as the
difference between 1-year volume and baseline volume,
divided by baseline volume).
Statistical analysis. Continuous variables are expressed as
mean  SD. Categorical data are summarized as frequen-
cies and percentages. Baseline clinical characteristics were
compared between the prespecified subgroups stratified
according to baseline LVEF by using the Kruskal-Wallis
test for continuous variables and the chi-square test or
Fisher exact test for dichotomous variables, as appropriate.
The correlation of LVEF identified by the centers and
measured by the echocardiography core laboratory was
analyzed by using the Spearman’s rank correlation method.
The correlation of baseline LVEF, QRS duration, and left
ventricular volumes were assessed by using the Pearson’s
correlation method. Regression models were conducted to
evaluate the relation between baseline dyssynchrony and the
degree of echocardiographic response to CRT (defined as
percent change in LVESV at 1 year) within each ejection
fraction (EF) category.
Cumulative probability of first HF or death events
according to baseline LVEF and treatment arm within each
LVEF group was displayed according to the Kaplan-Meier
method, with comparisons of cumulative event rates accord-
ing to the log-rank test. Multivariate Cox proportional hhazards regression analysis was used to identify and evaluate
the impact of LVEF groups on the endpoint of HF/death or
death. The Cox model was adjusted for relevant clinical
covariates by using best subset regression modeling.
All statistical tests were 2-sided; a p value 0.05 was
considered statistically significant. Analyses were conducted
by using SAS version 9.2 (SAS Institute, Inc., Cary, North
Carolina).
Results
At baseline, 914 patients (50.5%) had LVEF 26% to 30%
(median 28.1%; quartile [Q] Q1 27.1%; Q3 29.0%),
and 199 patients (11%) comprised the LVEF group of
25% (median  23.2%; Q1  21.8%; Q3  24.2%). The
subgroup of LVEF30% included 696 (38%) patients (in the
range of 30.1% to 45.3%; median  31.8%; Q1  30.8%;
Q3  33.1%), as evaluated by the echocardiography core
laboratory.
LVEFs identified by the enrolling centers were multiples
of 5 in 72% of cases, possibly due to the fact that most
centers used estimates for this measure. There was a weak
but significant correlation between LVEFs identified by the
centers and measured by the echocardiography core labora-
tory (r2  0.105, p  0.001). The distribution and corre-
ation of LVEF identified by the enrolling centers and
easured by the echocardiography core laboratory are
hown in Figure 1.
The baseline clinical characteristics of patients with
VEF 25%, LVEF 26% to 30%, and LVEF 30% are
hown in Table 1. Patients with increasing LVEF were
lder, more often female, had a lower heart rate, less often
ad left bundle branch block and more often right bundle
ranch block, and had an intraventricular conduction delay
lectrocardiography pattern. There was a trend toward more
requent ischemic cardiomyopathy and fewer previous epi-
odes of severe HF (3 months before enrollment) with less
epressed LVEF. Baseline drug treatment was similar
cross LVEF ranges, with less use of diuretics and digitalis
ith increasing LVEF. Echocardiographic results showed
radually smaller LVEDV, LVESV, and LAVs across
VEF groups, demonstrating less advanced stage of the
isease.
Baseline LVEF was inversely related to baseline QRS
r  0.22, p  0.001), and left ventricular volumes
LVEDV index r  0.35, p  0.001; LVESV index r 
.36, p  0.001), suggesting that these parameters were
ighly correlated in MADIT-CRT.
ffect of baseline LVEF on primary clinical outcome and
ll-cause mortality. The primary endpoint of HF or death
as met in 375 patients (20.7%) with baseline LVEF
easurements; 126 patients (7%) died, 78 (4.3%) of cardiac
auses during the mean follow-up of 29.4  11 months.
Patients with baseline LVEF 25% showed significantly
igher cumulative incidence of HF or death episodes
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30% (Fig. 2A).
The multivariate Cox model after adjustment for relevant
clinical covariates (treatment, ischemic etiology of cardio-
myopathy, NYHA class III or IV greater than 3 months
before enrollment, baseline heart rate, and age at enroll-
ment) revealed similar findings. Patients with LVEF 25%
had 55% higher risk of HF or death compared with patients
with LVEF 26% to 30%, and 66% higher risk compared
with patients with LVEF 30%. Patients with LVEF 26%
to 30% and LVEF 30% demonstrated a similar risk of
HF/death. LVEF as a continuous measure was a surrogate
marker of the primary endpoint, demonstrating a significant
5% reduction in the risk of HF/death for each unit incre-
ment in LVEF (Table 2).
Patients had low and similar incidence of all-cause
mortality irrespective of their LVEF group at baseline
(3-year Kaplan-Meier cumulative event rates in LVEF
25%: 9%; LVEF 26% to 30%: 8%; LVEF 30%: 8% [p
log-rank test  0.709]) (Fig. 2B). This finding was con-
firmed in the multivariate model after adjustment for
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Figure 1 Distribution of Baseline LVEF Identified by the Center
and Measured by the Echocardiography Core Laborato
Left ventricular ejection fractions (LVEFs) identified by the enrolling centers were m
rather than a more quantitative approach. Accordingly, the LVEF values identified b
phy core laboratory–measured LVEFs that had a normal, Gaussian distribution pat
LVEF identified by the enrolling centers.relevant clinical covariates (data not shown).Effect of CRT therapy on the primary clinical outcome
and all-cause mortality by LVEF. Evaluating the treat-
ment effects of CRT-D versus ICD-only therapy, 1,809
patients (1,074 CRT-D patients and 735 ICD patients)
with baseline LVEF data available were analyzed on an
intention-to-treat basis.
Univariate Kaplan-Meier survival analysis showed that
compared with ICD-only therapy, treatment with CRT-D
showed borderline significance in decreasing the cumulative
incidence of HF/death in patients with LVEF 25% (p 
0.062). This effect was statistically significant among pa-
tients with LVEF 26% to 30% (p  0.003) and with LVEF
30% (p  0.009) (Fig. 3).
Consistent with these findings, the multivariate Cox
model after adjustment for relevant clinical covariates found
that CRT-D treatment was associated with a significant
43% reduction in the risk of HF or death in patients with
LVEF 25% (p  0.03), a 33% risk reduction in patients
with LVEF 26% to 30% (p  0.007), and a significant 44%
risk reduction among those with LVEF 30% (p  0.003).
The interaction p value was not significant for all LVEF
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LVEF and CRT March 5, 2013:936–440.10), indicating that the clinical benefit of CRT-D was
maintained regardless of baseline LVEF (Table 3).
The treatment effect on the endpoint of all-cause mor-
tality was neutral in patients with LVEF 25% (hazard
ratio [HR]: 1.49 [95% confidence interval (CI): 0.60 to
3.70], p  0.387), LVEF 26% to 30% (HR: 0.89 [95% CI:
.54 to 1.46], p  0.647), and LVEF 30% (HR: 0.85
95% CI: 0.46 to 1.58], p  0.614), possibly due to the
relatively low rate of mortality events in each LVEF group
during the trial (Fig. 2B).
The magnitude of echocardiographic response to CRT-D
by LVEF groups. Echocardiographic response was assessed
at 12-month follow-up in patients with implanted CRT-D;
crossovers were excluded from this analysis (n  119).
Echocardiographic response to CRT-D was directly cor-
related to LVEF. Patients with LVEF 25% exhibited less
decrease of LVEDV percent change from baseline to 1 year
(18.7  11.6%) compared with patients with LVEF 26%
to 30% (20.1  10.7%) or patients with LVEF 30%
(22.3  12.3%) (p  0.001). Furthermore, patients with
LVEF 30% showed a significantly greater reduction in
LVEDV than patients with LVEF 26% to 30% (p  0.001).
Similarly, the degree of LVESV percent reduction with
CRT-D therapy was also directly correlated to increasing
LVEF groups (31.4  13.5% change vs. 32.0  13.8%
vs. 33.6  17.1% change; p  0.001 for the overall
difference). Patients with LVEF 30% exhibited a greater
reduction in LVESV than patients with LVEF 26% to 30%
Clinical Characteristics of All Patients in TermsTable 1 Clinical Characteristics of All Patie
Clinical Characteristic
L
Age (yrs)
Females
CRT-D treatment
Ischemic NYHA class I
Ischemic NYHA class II
Nonischemic NYHA class II
Worst NYHA class 2 (3 months before enrollment)
QRS complex (ms) 1
LBBB
RBBB
IVCD
Heart rate
Systolic blood pressure 1
ACE inhibitors/ARB
Beta-blocker
Diuretics
Digitalis
LVEDV indexed by BSA 1
LVESV indexed by BSA 1
LAV indexed by BSA
Values are mean  SD or n (%) of patients.
ACE angiotensin-converting enzyme; ARB angiotensin receptor
with defibrillator; IVCD  intraventricular conduction delay; LAV lef
end-diastolic volume; LVEF  left ventricular ejection fraction; LVESV
NYHA  New York Heart Association; RBBB  right bundle branch blo(p  0.029).Consistent findings were seen in LAV reduction
(22.67  10.9% vs. 27.6  11.6% vs. 30.4  12.5%;
p 0.001). Again, patients with LVEF30% gained more
ronounced left atrial remodeling than those with LVEF
6% to 30% (p  0.001) (Fig. 4).
We also analyzed LV dyssynchrony data available in 587
61.5%) of 955 patients undergoing CRT-D. Patients with
VEF 25% exhibited greater baseline left ventricular
yssynchrony (207.1  63.1 ms) compared with patients
ith LVEF 26% to 30% (194  64.4 ms) or LVEF 30%
175.5  65.3 ms) (p  0.001). However, the reduction in
left ventricular dyssynchrony at 12 months of follow-up was
similar across LVEF groups (13.4  49.1% vs. 19.0 
43.0% vs. 14.0  55.8% change; p  0.93). We further
correlated the relation between baseline dyssynchrony and the
degree of echocardiographic response to CRT (defined as
percent change in LVESV at 1 year) within each EF category
prespecified by using a regression model. This analysis showed
that among patients with LVEF 30% and LVEF 26% to
30%, the degree of baseline dyssynchrony was directly corre-
lated with the percent reduction in LVESV (p  0.001 for
both categories). Among those with a lower LVEF, there was
no correlation between dyssynchrony and echocardiographic
response to CRT (p  0.99).
Discussion
Our study demonstrates that patients with mild HF with
aseline LVEF RangesTerms of Baseline LVEF Ranges
25%
99)
LVEF 26% to 30%
(n  914)
LVEF >30%
(n  696) p Value
11.0 64.3 10.8 65.3 10.4 0.001
18) 220 (24) 195 (28) 0.012
58) 554 (61) 416 (60) 0.755
13) 121 (13) 118 (17) 0.077
37) 388 (42) 267 (38) 0.162
50) 405 (44) 311 (45) 0.300
13) 102 (12) 56 (8) 0.063
22.5 159.1 20.0 154.4 17.6 0.001
84) 656 (72) 450 (65) 0.001
5) 111 (12) 106 (15) 0.001
11) 146 (16) 139 (20) 0.006
12.0 67.8 10.6 67.0 10.7 0.007
17.5 121.9 16.7 124.4 18.1 0.001
82) 685 (75) 546 (78) 0.168
90) 854 (93) 653 (94) 0.236
71) 653 (69) 446 (64) 0.035
34) 241 (26) 156 (22) 0.003
40.7 125.5 26.7 112.9 19.1 0.001
32.4 90.5 19.8 76.6 13.7 0.001
10.7 48.4 8.8 41.2 7.9 0.001
; BSA body surface area; CRT-D cardiac resynchronization therapy
volume; LBBB  left bundle branch block; LVEDV  left ventricular
entricular end-systolic volume;of Bnts in
VEF <
(n  1
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March 5, 2013:936–44 LVEF and CRTquent HF or death compared with patients with LVEF 26%
to 30% or LVEF 30%. However, the clinical benefit of
CRT-D was maintained across all LVEF groups; the
echocardiographic response to CRT-D was even more
pronounced among patients with higher LVEFs, including
those with LVEF 30% (beyond the eligibility criteria of
this study). These findings suggest that mildly symptomatic
HF patients with LVEF 30% might be potential candi-
dates for CRT-D. Furthermore, this subset of patients may
derive a more favorable echocardiographic response to
CRT-D than patients currently indicated for treatment
with the device, which could translate into improved clinical
outcome during long-term follow-up.
Previous smaller studies have suggested that patients with
severe HF (NYHA III and IV) and higher baseline LVEF
could be eligible for CRT; they have shown improvement in
clinical status and echocardiographic parameters (16,17).
Figure 2
Kaplan-Meier Estimates of the Cumulative
Probability of Various Factors in all Patients With
LVEF <25%, LVEF 26% to 30%, and LVEF >30%
(A) Heart failure (HF)/death episodes. (B) All-cause mortality. Patients with
baseline LVEF 25% showed significantly higher cumulative incidence of HF or
death episodes compared with patients with LVEF 26% to 30% or LVEF 30%
(3-year cumulative event rates for LVEF 25%: 31%; LVEF 26% to 30%: 22%;
LVEF 30%: 22%). Patients with an LVEF of 26% to 30% and 30% had simi-
lar cumulative probability of HF/death. The incidence of all-cause mortality was
similar and low in all LVEF subgroups. Abbreviations as in Figure 1.Recently, Chung et al. (18) reported that 86 (24%) of 361patients enrolled in the PROSPECT (Predictors of Re-
sponse to Cardiac Re-Synchronization Therapy) trial had
LVEF 35% measured by the echocardiography core lab-
oratory. They found that CRT improved the clinical com-
posite score and was associated with similar decrease of
LVESV in patients with LVEF 35% or 35%. The
REVERSE trial included patients with mild HF and LVEF
40% (6); however, the mean LVEF in the study was low
(26.8 7.0% in the group with the CRT device turned ON
[CRT ON] CRT-ON arm), indicating that the proportion
of patients with better LVEF might have been small. In
contrast to the PROSPECT substudy, our analysis showed
that patients with LVEF 30% exhibited even more
pronounced echocardiographic response to CRT-D than
patients with lower LVEF.
The findings of this analysis seem to be in contrast to
previous data that the sickest patients may benefit most
from device therapy due to increased long-term risk (19).
However, we suspect that as with most therapies, there is a
“sweet spot” for CRT, whereby there may be benefit as
ventricular function worsens to some extent, but that when
ventricular function worsens beyond a certain level, there is
no further benefit because the ventricle becomes too “sick”
to respond.
The importance of a preventive strategy in HF has been
demonstrated by a study by Gasparini et al. (20); in a
population of 500 patients, 26% achieved left ventricular
remission (defined as return to NYHA I and EF 50%).
Notably, in multivariate analysis, an LVEF 30% to 35% and
LVEDV 180 ml were strongly associated with the HF
emission phase. We have shown similar effect in the current
nalysis in patients with mild HF and CRT implantation.
Notably, patients with LVEF 30% showed a clinical
esponse to CRT-D similar to that of patients with lower
VEF, despite the fact that they had a higher frequency of
ight bundle branch block and intraventricular conduction
elay and less wide QRS durations, characteristics which
ere proven to be associated with unfavorable response in
ADIT-CRT (21). There was a significant correlation
etween baseline QRS duration and LVEF and baseline
RS duration and LVEDV/LVESV index. Furthermore,
atients with LVEF 30% had significantly smaller end-
iastolic and end-systolic volumes, indicating less advanced
Baseline LVEF Groups and the Risk of HF/DeathTable 2 Baseline LVEF Groups and the Risk of HF/Death
Parameter
HF/Death
Hazard Ratio 95% CI p Value
LVEF 25 %: LVEF 26% to 30% 1.55 1.16–2.08 0.003
LVEF 25 %: LVEF 30% 1.66 1.21–2.28 0.002
LVEF 26% to 30 %: LVEF 30% 1.07 0.84–1.36 0.588
LVEF (continuous) 0.95 0.92–0.98 0.001
Model was adjusted for treatment, ischemic etiology of cardiomyopathy, NYHA class 2 greater
than 3 months before enrollment, baseline heart rate, and age at enrollment.
HF  heart failure; CI  confidence interval; other abbreviations as in Table 1.
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LVEF and CRT March 5, 2013:936–44stage of the disease. This finding highlights the importance
of HF progression prevention in this patient population.
The risk of HF or death was significantly higher in the
patient group with LVEF 25%; however, the curves
diverged only after 1 year. This phenomenon might be
explained by the fact that those patients implanted with a
CRT-D device develop left ventricular reverse remodeling
within 1 year, which is associated with a subsequent
reduction in the risk of HF or death events. This mecha-
nism is consistent with a previous publication from
MADIT-CRT, which showed that changes in left ventric-
ular volumes with CRT therapy are highly correlated with
subsequent clinical outcomes (4).
Similar to the primary MADIT-CRT report, in which
treatment with CRT-D was not associated with a statistically
significant effect on the risk of all-cause mortality (12), the
current study also found no significant mortality reduction with
CRT-D in any of the LVEF subgroups. This can be
explained by the fact that patients with asymptomatic or
mild HF enrolled in MADIT-CRT experienced a relatively
low rate of death during the trial, possibly requiring a longer
follow-up period to show a significant mortality benefit
from the device.
We found a significant reduction in LAV in all 3 LVEF
groups, which might be explained by significant reduction in
mitral regurgitation as reported in the total CRT-D popula-
Figure 3 Kaplan-Meier 2.5-Year Event Rates of the Cumulative
by Treatment Arm in Patients With LVEF <25%, LVEF
Cardiac resynchronization therapy with defibrillator (CRT-D) treatment was associat
in patients with LVEF 25% (p  0.062), and a statistically significant decrease
cardioverter-defibrillator (ICD)-treated patient population. Importantly, patients with b
tion compared with ICD-only. p  0.05 for comparison between ICD and CRT-D treatmtion compared with ICD patients (published elsewhere[4,22]). Another publication from our group evaluated the
reduction in LAV and subsequent decrease in atrial arrhyth-
mias, suggesting that reduction in LAV was associated with
significantly lower risk of atrial arrhythmias (22). Therefore, we
hypothesize that patients with LVEF 30% have more sig-
nificant reduction in LAV, probably due to a more pronounced
decrease in mitral regurgitation that might be associated with
lower risk of atrial arrhythmias during follow-up. Furthermore,
LAV often reflects the cumulative effects of left ventricular
filling pressures over time and thus may provide a more
sensitive morphophysiologic expression of the remodeling
effects of CRT than the left ventricle.
The relationship of baseline dyssynchrony and clinical
outcome in MADIT-CRT has been reported earlier (4).
riefly, those patients with mild to moderate baseline
Treatment Effect of CRT-D StratifiedAccording to Baseline LVEF Groupsfor the Primary Endpoint of HF/Death
Table 3
Treatment Effec of CRT-D Stratified
According to Baseline LVEF Groups
for the Primary Endpoint of HF/Death
Parameter
Endpoint: HF/Death
Hazard Ratio 95% CI p Value
LVEF 25% 0.57 0.35–0.95 0.031
LVEF 26% to 30% 0.67 0.50–0.90 0.007
LVEF 30% 0.56 0.39–0.82 0.003
Model was adjusted for female sex, ischemic etiology, and QRS duration. Interaction p values with
ability of HF/Death Episodes
to 30%, and LVEF >30%
h a borderline significant decrease in the cumulative incidence of HF or death
ents with LVEF 26% to 30% (p  0.003), compared with the implantable
LVEF 30% (p  0.009) gained significant benefit of CRT-D in HF and death reduc-
s. Abbreviations as in Figures 1 and 2.Prob
26%
ed wit
in pati
aseline
ent armtreatment are 0.1 in all patient groups and LVEF subgroups.
Abbreviations as in Tables 1 and 2.
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March 5, 2013:936–44 LVEF and CRTdyssynchrony demonstrated the greatest benefit from
CRT-D, whereas those with lower or higher degrees of
dyssynchrony derived a lower benefit, displaying a J-shaped
pattern within quartiles. In the current analysis, it also seems
that patients with a lower EF, who had a greater degree of
baseline dyssynchrony, had a lower echocardiographic re-
sponse to CRT compared with patients in the higher EF
categories. This finding is further supported by the corre-
lation of dyssynchrony and echocardiographic response in
the LVEF 26% to 30% group and the LVEF 30% group,
whereas patients with LVEF 25% did not show associa-
ion between dyssynchrony and echocardiographic response.
hese results differ from previous reports among patients
ith more advanced HF symptoms, in which there was a
irect correlation between the degree of dyssynchrony and
esponse to CRT. Thus, our findings regarding the inter-
ction among baseline LVEF, dyssynchrony, and response
o CRT may be unique to the patients with mild HF who
re treated with the device.
The current study found a pronounced difference
etween the echocardiographic assessment of LVEF at
he sites and the central core laboratory assessment. Thus,
8% of the patients who were identified by the centers as
aving LVEF 30%, and therefore deemed eligible for the
tudy, were subsequently determined by the core laboratory
s having LVEF 30%. These differences are similar to
hose shown in the PROSPECT study (18) and may be
ossibly explained by the fact that a nonblinded reading of
ardiac function can be biased by the patient’s condition,
nd by inclusion bias, and may therefore underestimate
VEF. LVEF identified by the centers were in multiples of
in 72% of cases, suggesting that sites used visual estima-
ion rather than a more quantitative approach (as was used
Figure 4 Effects of CRT-D on Echocardiographic Parameters Af
in Patients With LVEF <25%, LVEF 26% to 30%, an
Echocardiographic response to CRT-D was directly correlated to LVEF. Patients wit
diastolic volume (LVEDV) percent change, left ventricular end-systolic volume (LVE
pared with patients with LVEF 26% to 30% or with patients with LVEF 30%. Furth
LVESV, and LAV than patients with LVEF 26% to 30%.n the core laboratory).This is the first report of data presented from a large
patient cohort analyzing the impact of baseline LVEF,
including those with LVEF30% on the primary endpoint
of HF or death in patients with NYHA class I or II
undergoing CRT implantation.
Study limitations. This is a post hoc analysis by echocar-
diographic groups that were not part of the original design
of MADIT-CRT, and the incomplete datasets or images
with poor quality were excluded from the analysis. Another
possible limitation is that some study patients with images
at baseline might be deactivated from the study or die before
the 1-year reassessment. Our results did not show a statisti-
cally significant difference in the benefit of CRT-D for the
primary endpoint among the EF subgroups according to
interaction term analyses. However, the lack of statistical
significance of the interaction tests may be related to sample
size and the number of primary endpoint events in
MADIT-CRT.
Conclusions
We demonstrated that the clinical benefit of CRT is present
regardless of LVEF groups in patients enrolled in MADIT-
CRT, including those with LVEF 30% (beyond the eligi-
bility criteria). The echocardiographic response was directly
correlated with increasing LVEF, indicating that patients with
better baseline LVEF may derive benefit from CRT.
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F >30%
25% at baseline showed less pronounced decrease of left ventricular end-
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